Personal Introduction

EDUCATION

• B.S. in Clinical Medicine, 1995, Nanjing Medical University, Nanjing China

• Ph.D. inImmunology, 2000, Nanjing Medical University, Nanjing China

ACADEMIC POSITIONS/EMPLOYMENT/EXPERIENCE:

• 2001-2005 Postdoctoral Fellow, Baylor College of Medicine, Houston, TX.

• 2006-2012 Senior Research Scientist, Department of Pathology, School of Medicine, Stanford University, Stanford, CA.

• 2013-Present Professor of Department of Immunology and Microbiology, Principal Investigator of Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Research Interests

We focus on the interaction between the immune system and metabolism in the context such as metabolic diseases where immune cells modulate whole-body metabolism, and immune cells development where cell-intrinsic metabolic programs control the fate and function of immune cells. Our lab current research directions include:

• 1. To define the immune mechanisms of obesity-induced insulin resistance;

• 2. To decipher the metabolic programs that control Innate Lymphoid Cells (ILC) development and function.

Scientific Research Projects

• 2020-2025: The National Key R&D Program of the Ministry of Science and Technology "Protein Machine and Life Process Regulation" key project, participating in the study of protein machine in the interaction between infection of important intestinal pathogens and key host factors to promote the occurrence and development of colorectal cancer, project ID: 2020YFA0509, 200November 2020 to October 2025

• 2020-2023: General Program of National Natural Science Foundation of China, Principal Investigator, Liver kinase B1 (LKB1) regulates the function of adipose type 2 innate lymphocytes (ILC2) and affects the occurrence of obesity and type 2 diabetes, project number #81971487

• 2020-2023: Shanghai Natural Science Foundation Project, Principal Investigator, The role and mechanism of SUMO-specific protease 1 (SENP1) in regulating B cell germinal center response and antibody class switching, project number: 20ZR1430200

• 2020-2022: Shanghai "Science and Technology Innovation Action Plan", principal, development and application of FACSymphony high-parameter flow analyzer for panoramic immune monitoring, project number: 20142202300

• 2020-2022: Bidi Medical Devices (Shanghai) Horizontal Project, Principal, Application of scRNAseq and high-parameter flow cytometry to analyze the immune response characteristics of innate lymphocytes in colon cancer tumor microenvironment, project number: 2020HX009

• 2016-2019: General Program of National Natural Science Foundation of China, Principal Investigator, Regulation of SUMO-specific protease 1 on adipose tissue macrophages and its relationship with type 2 diabetes, project number: #81571533

• 2016-2019: General Program of National Natural Science Foundation of China, Principal Investigator, Research on the regulation and mechanism of PLZF on the development and function of type 3 innate lymphocytes (ILC3), project number: #31570921

• 2016-2018: National Nature Major Research Program, Participant, Mechanism of Dermo+ Interstitial Cells in Intestinal Immune Response, Project ID: # 91542120

• 2014-2017: General Project of National Natural Science Foundation of China, Principal Investigator, Mechanism of B lymphocytes in regulating obesity-induced insulin resistance, project number: #81373210

• 2014-2017: National Overseas High-level Talent Program, Principal, Adaptive Immune Response and Type 2 Diabetes

• 2013-2015: Shanghai Pujiang Talent Program, Principal, Mechanism of B cell subsets in insulin resistance, project number: #13PJ1405400

Publications

1. Zhang J，Qiu J, Zhou W, Cao J, Hu X, Mi W, Su B, He B, Qiu J, Shen L*. Neuropilin-1 mediates lung tissue-specific control of ILC2s function in type 2 immunity. Nature Immunology (2022). https://doi.org/10.1038/s41590-021-01097-8

2. ChenZ，XieX，JiangN,Li J, Shen L*, Zhang Y*. CCR5 signaling promotes lipopolysaccharide-induced macrophage recruitment and alveolar developmental arrest. Cell Death Dis.2021 Feb 15;12(2):184. doi: 10.1038/s41419-021-03464-7.

3. Shen L,Ye Y, Sun H,Su B. ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy. Cancer Cell. 2021 Aug 13:S1535-6108(21)00442-6. doi: 10.1016/j.ccell.2021.08.002.

4. Gao L, Yu Q, Zhang HS, Wang ZT, Zhang T, Xiang J, Yu S, Zhang S,Wu H, Xu Y, Wang Z, Shen L,Shu G, Chen YG, Liu H, Shen L*,Li1 BJ*. A resident stromal cell population actively restrains innate immune response in the propagation phase of colitis pathogenesis in mice. SciTransl Med.2021 Jul 21;13(603):eabb5071. doi: 10.1126/scitranslmed.abb5071.

5. Qi JJ, Crinier A, Escalière B, Ye YQ, Wang Z, Zhang TY, Batista L, Liu H, Hong L, Liu Y, Shen L*, Vivier E*, Su B*. Single cell transcriptomic landscape reveals tumor specific innate lymphoid cells associated with colorectal cancer progression. Cell Rep Med. 2021 Jul 27;2(8):100353. doi: 10.1016/j.xcrm.2021.100353.

6. Qiu J, Zhang J, Ji Y, Sun H, Gu Z, Sun Q, Bai M, Gong J, Tang J, Zhang Y, Li S, Shao Z, Li J, Sheng H*, Shen L*, Qiu J*. Tissue signals imprint Aiolos expression in ILC2s to modulate type 2 immunity. Mucosal Immunol. 2021 Aug 4. doi: 10.1038/s41385-021-00431-5..

7. 4. Li C, Liu J, Pan J, Wang Y, Shen L*, Xu Y*. ILC1s and ILC3s Exhibit Inflammatory Phenotype in Periodontal Ligament of Periodontitis Patients. Front Immunol. 2021 Jul 26;12:708678. doi: 10.3389/fimmu.2021.708678.

8. Ji Z, Wu S, Xu Y, Qi J, Su X, Shen L*. Obesity promotes EAE through IL-6 and CCL-2-mediated T cells infiltration. Front Immunol. 2019 Aug 27;10:1881.

9. Cai T, Qiu J, Ji Y, Li W, Ding Z, Suo C, Chang J, Wang J, He R, Qian Y, Guo X, Zhou L, Sheng H, Shen L*, Qiu J. IL-17-producing ST2+ group 2 Innate Lymphoid Cells play a pathogenic role in lung inflammation. J Allergy Clin Immunol. 2019, 143(1):229-244

10. Wang H, Shen L*, Sun X, Liu F, Feng W, Jiang C, Chu X, Ye X, Jiang C, Wang Y, Zhang P, Zang M, Zhu D, Bi Y. Adipose group 1 innate lymphoid cells promote adipose tissue fibrosis and diabetes in obesity. Nat Commun. 2019, 10(1):3254

Patent

• Modulation of cytokine signaling regulators and applications for Immunotherapy”, Licensing to ImmunoVac in April 2007. US Application Number:WO 2005US22396, US Publication Number: US7868158 B2.